VCP and cancer: We show that Jurkat tumoral cells, and also other leukemic human cells, such as U937 and Mec1, are more sensitive to cell death induced by the VCP inhibitor DBeQ than normal human T cells, suggesting a new selective pathway to exploit in cancer treatment.